Apricus Biosciences (APRI) Stock Price, News & Analysis

Company Overview

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. The firm's portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior in Major Depressive Disorder �or Post-Traumatic Stress Disorder, �amyotrophic lateral sclerosis, Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases. The company was founded by Raj Mehra in 2016 and is headquartered in New York, NY.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 2 shs
• Average Volume: 558,386 shs
• Market Capitalization: $14 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

APRI Stock Analysis - Frequently Asked Questions

How were Apricus Biosciences' earnings last quarter?

Apricus Biosciences, Inc. (NASDAQ:APRI) issued its quarterly earnings results on Wednesday, October, 31st. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.02.

What other stocks do shareholders of Apricus Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Apricus Biosciences investors own include Scotts Miracle-Gro (SMG), Pfizer (PFE), Just Eat Takeaway.com (GRUB), Boston Beer (SAM), Amicus Therapeutics (FOLD), Synergy Pharmaceuticals (SGYP).

Company Calendar

• Last Earnings: 10/31/2018
• Today: 8/26/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:APRI
• CIK: 1017491
• Web: www.apricusbio.com
• Phone: (646) 293-2100
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $320 thousand
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -216.45%
• Return on Assets: -153.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.86
• Quick Ratio: 3.86

Sales & Book Value

• Annual Sales: $5.76 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.29 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 28,170,000
• Free Float: N/A
• Market Cap: $14 thousand
• Optionable: Not Optionable
• Beta: 1.20